MarketLens
Sign Up

Celcuity's Gedatolisib: Regulatory Win Meets Commercial Reality

3 months ago
SHARE THIS ON:

Celcuity's Gedatolisib: Regulatory Win Meets Commercial Reality

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

Celcuity: REVTORPYK Is Now A Commercial Story

Celcuity's REVTORPYK/gedatolisib gained FDA approval and NCCN Category 1 inclusion, de-risking adoption. SG&A surged for launch, but a $754M cash position funds operations into 2029, supporting a pote...
Stock News•2 months ago

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics selected zovegalisib plus atirmociclib as its go-forward triplet regimen for first-line breast cancer, with a Phase 3 trial in endocrine-sensitive patients expected to start in earl...
Stock News•3 months ago

AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues

AstraZeneca won EU approval for breast-cancer drug camizestrant, opening a major market as U.S. regulators continue reviewing the application.

Breaking News

View All →

Top Headlines

View More →
Stock News•53 minutes ago

Amazon cloud capacity sold out through 2027, CEO Jassy says

Stock News•1 hour ago

GE Vernova (GEV) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•2 hours ago

Hottest toy for Christmas? Nvidia CEO plays with adorable Microduck robots, 20,000 sell

Stock News•2 hours ago

Turmoil hits AI buildout as neoclouds face pressure, credit risks mount and Solidigm pulls IPO

Stock News•3 hours ago

Kaplan Fox Notifies Investors of Alphabet Inc. (GOOGL, GOOG) of the Lead Plaintiff Deadline on December 1, 2026